| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| autologous t-cell therapy | t-cell surface glycoprotein cd3 epsilon | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of prostate[MeSHID:D011471] |
NA | phase 1 | unknown |
| autologous t-cell therapy | t-cell surface glycoprotein cd3 gamma | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of prostate[MeSHID:D011471] |
NA | phase 1 | unknown |
| autologous t-cell therapy | glutamate carboxypeptidase ii | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of prostate[MeSHID:D011471] |
NA | phase 1 | unknown |
| click here to return to the previous page | ||||||||